Table 3.
Univariable and multivariable analyses for overall survival.
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Median OS (days) | p | OR [95% CI] | p | |
| Age ⩾75 <75 |
441 452 |
0.85 |
||
| ECOG 0–1 ⩾2 |
468 362 |
0.054 |
||
| Bone marrow blasts (%) <30 ⩾30 |
459 211 |
0.003 |
2.13 [1.14–3.96] | 0.01 |
| Bone marrow blasts (%) <20 ⩾20 |
468 333 |
0.17 |
||
| Cytogenetic Good or intermediate Unfavorable |
592 354 |
<0.0001 |
1.7 [1.30–2.24] | <0.001 |
| Hb ⩾9 g/dl <9 g/dl |
496 366 |
0.045 |
||
| ANC >0.8 g/l ⩽0.8 g/l >0.5 g/l ⩽0.5 g/l |
441 453 459 441 |
0.85 0.83 |
||
| Platelets ⩾50 g/l <50 g/l |
538 373 |
<0.001 |
1.69 [1.3–2.2] | <0.001 |
| Infection in first four cycles No Yes |
534 342 |
<0.0001 |
1.43 [1.09–1.88] | 0.01 |
| Fluoroquinolone prophylaxis | Global | ANC <0.5 × 109/l | AML | |
| FQ yes | 424 | 434 | 346 | |
| FQ no | 476 | 452 | 304 | |
| HR | 1.2 | 1.08 | 0.89 | |
| [95% CI] | [0.95–1.5] | [0.68–1.73] | [0.95–1.5] | |
| p | 0.7 | 0.73 | 0.13 | |
AML, acute myeloid leukemia; ANC, absolute neutrophil counts; CI, confidence interval; CMML, chronic myelomonocytic leukemia; ECOG, Eastern Cooperative Oncology Group; FQ, fluoroquinolone; Hb, hemoglobin; HR, hazard ratios; MDS, myelodysplastic syndrome; OS, overall survival; WHO, World Health Organization.